Disease progression patterns of bevacizumab responders with recurrent malignant gliomas

Tumor progression in patients with recurrent malignant glioma who respond to bevacizumab (BEV) is difficult to assess. The current study reviewed the clinical and radiological results of patients following a BEV-based chemotherapy regimen, and evaluated disease progression patterns in patients who r...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncol Lett
Autors principals: Kim, Ju-Hwi, Jung, Tae-Young, Hwang, Eu Chang, Jung, Sung-Hoon, Jung, Shin, Kim, In-Young, Jang, Woo-Youl, Moon, Kyung-Sub, Lee, Kyung-Hwa, Kim, Seul-Kee
Format: Artigo
Idioma:Inglês
Publicat: D.A. Spandidos 2017
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5588053/
https://ncbi.nlm.nih.gov/pubmed/28927109
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2017.6630
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars